Europe RFID in Pharmaceuticals Market Report Scope & Overview:

Europe RFID in Pharmaceuticals Market was valued at USD 0.96 Billion in 2025 and is expected to reach USD 1.90 Billion by 2035, growing at a CAGR of 7.05% from 2026-2035.

The Europe RFID in Pharmaceuticals Market is expanding as drug manufacturers and wholesale distributors deepen compliance with the EU Falsified Medicines Directive, driving continued investment in item-level verification infrastructure across the region’s pharmaceutical supply chain. Growing adoption of sensor-enabled tags is extending traceability into cold-chain condition monitoring for biologics and vaccines distributed across increasingly fragmented national healthcare systems. Leading European tag and labelling suppliers continue to expand sterilization-ready and chipless product portfolios suited to vials, syringes, and other harsh-environment pharmaceutical packaging formats. Rising integration between RFID infrastructure and cloud-based EPCIS analytics platforms is further strengthening end-to-end visibility across cross-border European distribution networks.

⮞Schreiner MediPharm and HERMA announced an integrated RFID labelling solution for pharmaceutical vials in May 2026, reflecting continued European supplier investment in labelling technology tailored to the region’s stringent packaging and serialization requirements.

Germany RFID in Pharmaceuticals Market Outlook

Germany RFID in Pharmaceuticals Market was valued at USD 0.25 Billion in 2025 and is expected to reach USD 0.46 Billion by 2035, growing at a CAGR of 6.20% from 2026-2035.

The Germany RFID in Pharmaceuticals Market is advancing as drug manufacturers and wholesale distributors deepen Falsified Medicines Directive compliance while hospital pharmacies across the country continue modernizing inventory and anti-diversion systems. Schreiner MediPharm’s continued investment in integrated labelling solutions, including its recent collaboration with HERMA, is reinforcing Germany’s position as a center of European RFID labelling innovation for pharmaceutical vials. Growing biologics and vaccine manufacturing across the country is widening demand for sensor-enabled tags capable of continuous cold-chain condition monitoring from production through distribution. Continued investment by domestic and international suppliers in sterilization-compatible product lines is further broadening adoption across the German pharmaceutical packaging landscape.

Germany’s pharmaceutical industry association has flagged a difficult near-term path for domestic chemical and pharmaceutical manufacturing output heading into 2026, a factor expected to moderate the pace of new RFID capital investment relative to faster-growing European markets.

Europe RFID in Pharmaceuticals Market Segment Analysis

• By Component, RFID Tags dominate the Europe RFID in Pharmaceuticals Market with 44.50% share in 2025; RFID Middleware is expected to grow at the fastest CAGR of 9.40% from 2026–2035.

• By Type, Chipped RFID dominates the Europe RFID in Pharmaceuticals Market with 70.80% share in 2025; Chipless RFID is expected to grow at the fastest CAGR of 9.60% from 2026–2035.

• By Application, Drug Tracing & Authentication dominates the Europe RFID in Pharmaceuticals Market with 51.60% share in 2025; Drug Quality & Condition Monitoring is expected to grow at the fastest CAGR of 9.90% from 2026–2035.

• By End User, Drug Manufacturers dominate the Europe RFID in Pharmaceuticals Market with 47.60% share in 2025; Retail & E-Pharmacies are expected to grow at the fastest CAGR of 10.05% from 2026–2035.

By Component, RFID Tags Dominate the Europe RFID in Pharmaceuticals Market, RFID Middleware Grows Fastest

RFID tags retained the largest component share across Europe in 2025, supported by their low unit cost, straightforward integration into existing packaging lines, and mandatory status under Falsified Medicines Directive serialization requirements for prescription drugs. European suppliers including Tageos and Schreiner MediPharm have scaled high-volume inlay and labelling production to meet steady demand from drug manufacturers maintaining compliance across fragmented national healthcare systems. Continued cost declines in chip-based and chipless tag manufacturing are reinforcing tags as the dominant revenue contributor across nearly every pharmaceutical packaging format even as middleware and software categories expand at a faster underlying rate through the forecast window.

RFID middleware is forecast to grow fastest through 2035 as drug manufacturers and wholesale distributors scale item-level verification programs that require reliable data capture, filtering, and transmission between readers and enterprise track-and-trace systems. Growing integration between on-site RFID infrastructure and cloud-based EPCIS analytics platforms is converting latent middleware demand into sustained software licensing and service growth faster than any other component category across the region. Expanding hospital and pharmacy chain deployments across Germany, France, and the United Kingdom, each requiring tailored middleware configuration, are further reinforcing this growth pattern through the remainder of the forecast period.

By Type, Chipped RFID Dominates the Europe RFID in Pharmaceuticals Market, Chipless RFID Grows Fastest

Chipped RFID tags remain the dominant type across Europe given their established read-range performance, mature supplier ecosystem, and broad compatibility with existing pharmaceutical serialization and track-and-trace infrastructure built up since the Falsified Medicines Directive took effect. NXP Semiconductors and Impinj continue to supply the chip platforms underpinning most drug manufacturer and distributor deployments, reinforcing chipped RFID as the default technology choice across nearly every application category in the region. This structural position is expected to persist through the remainder of the forecast period even as chipless alternatives gain traction in cost-sensitive, high-volume tagging use cases across the broader European pharmaceutical packaging landscape.

Chipless RFID is growing fastest as suppliers introduce sterilization-compatible inlay portfolios suited to vials, syringes, and other harsh-environment items where chip-based tags face cost or durability constraints across the region. Falling production costs for printed and chipless formats are converting latent demand among smaller drug manufacturers and packaging converters into sustained volume growth faster than any other type category across Europe. Continued expansion of chipless tag applications into blister packs and secondary packaging is expected to further reinforce this above-average growth trajectory through the remainder of the 2026-2035 forecast window as adoption broadens across the region.

By Application, Drug Tracing & Authentication Dominates the Europe RFID in Pharmaceuticals Market, Drug Quality & Condition Monitoring Grows Fastest

Drug tracing and authentication remains the largest application given direct regulatory pressure from the EU Falsified Medicines Directive, which requires manufacturers and distributors to maintain verifiable chain-of-custody records at the item level across the European pharmaceutical distribution network. Established serialization infrastructure built by major drug manufacturers over the past decade continues to anchor this application as the dominant revenue contributor across nearly every RFID deployment in the region. Growing enforcement activity across national healthcare systems is expected to keep tracing and authentication the primary driver of tag and reader purchasing decisions through the remainder of the forecast period.

Drug quality and condition monitoring is set to post the fastest growth as biologics and other temperature-sensitive therapies drive demand for sensor-enabled tags capable of continuous cold-chain tracking from manufacturing through last-mile delivery across Europe. Growing biologics manufacturing investment across Germany, France, and the United Kingdom is accelerating adoption of condition-monitoring RFID among drug manufacturers seeking to reduce spoilage-related losses and regulatory exposure. Rising integration of sensor data with cloud analytics platforms is expected to further reinforce this application’s above-average growth trajectory through the remainder of the 2026-2035 forecast window across the region.

By End User, Drug Manufacturers Dominate the Europe RFID in Pharmaceuticals Market, Retail & E-Pharmacies Grow Fastest

Drug manufacturers remain the largest end user given their direct regulatory obligation to serialize and verify products at the point of manufacture under the EU Falsified Medicines Directive across the region. Point-of-manufacture tagging programs adopted by major pharmaceutical producers continue to anchor this end-user category as the dominant revenue contributor across nearly every RFID component and application in Europe. Established supplier relationships between tag, reader, and middleware vendors and large drug manufacturers are expected to keep this group the primary purchaser of RFID infrastructure through the remainder of the forecast period as compliance activity continues across the region.

Retail and e-pharmacies are growing fastest as online prescription fulfillment expands across European markets and chains seek RFID-enabled inventory accuracy and anti-diversion controls across increasingly distributed fulfillment networks. Growing consumer reliance on online pharmacy ordering across Germany, France, and the United Kingdom is encouraging similar retail and e-pharmacy adoption as chains look to replicate inventory and cost-saving outcomes seen in other regions. This end user’s above-average growth trajectory is expected to continue through the remainder of the 2026-2035 forecast period as digital fulfillment volumes continue to climb across the region.

Regional Analysis

Germany RFID in Pharmaceuticals Market Insights

Germany dominated the Europe RFID in Pharmaceuticals Market with the highest revenue share of about 25.80% in 2025, supported by the scale of its pharmaceutical manufacturing base, a mature Falsified Medicines Directive compliance infrastructure, and the presence of leading labelling and tagging suppliers such as Schreiner MediPharm headquartered in the country. Continued investment in integrated RFID labelling solutions, including the recent collaboration between Schreiner MediPharm and HERMA, is reinforcing Germany’s position as a center of European pharmaceutical RFID innovation. Rising biologics and vaccine manufacturing investment across the country is expected to keep Germany the primary revenue engine for the regional market through the remainder of the forecast period.

Continued expansion of item-level serialization programs, growing biologics manufacturing investment, and sustained hospital and retail pharmacy modernization reinforce Germany’s dominance within Europe across nearly every component and application category. A cautious near-term outlook flagged by the country’s pharmaceutical industry association for 2026 is expected to moderate, though not reverse, the pace of new RFID capital investment relative to faster-growing European markets such as the United Kingdom. This structural position is expected to continue shaping purchasing and deployment decisions across the market through the remainder of the forecast period.

United Kingdom RFID in Pharmaceuticals Market Insights

The United Kingdom segment is expected to grow at the fastest CAGR of about 8.05% from 2026–2035, facilitated by growing National Health Service investment in hospital pharmacy automation and rising biologics manufacturing activity across the country’s life-sciences clusters. Growing retail pharmacy chain adoption of RFID-enabled inventory accuracy programs is reinforcing the United Kingdom’s above-regional growth trajectory as digital prescription fulfillment continues to expand nationwide. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as hospital networks continue modernizing medication tracking infrastructure.

Moreover, continued investment by major RFID suppliers in United Kingdom distribution and technical support infrastructure, combined with growing National Health Service interest in point-of-manufacture tagging, is supporting faster-than-average volume growth across the country through the forecast period. Expanding biologics and specialty drug manufacturing tied to the country’s established life-sciences base is expected to further reinforce the United Kingdom’s above-regional growth rate through 2035. Continued supplier coordination with regional hospital networks is expected to reinforce this pattern through the remainder of the decade across the broader United Kingdom pharmaceutical market.

France RFID in Pharmaceuticals Market Insights

France accounted for a steady share of the Europe RFID in Pharmaceuticals Market in 2025, supported by established pharmaceutical manufacturing clusters and a mature wholesale distribution network maintaining Falsified Medicines Directive compliance across the country. Growing investment in point-of-manufacture tagging among major French drug manufacturers continues to reinforce the country’s position as a consistent contributor to the regional market. Established relationships between domestic suppliers and large pharmaceutical producers further support steady volume growth through the remainder of the forecast period across the broader French pharmaceutical supply chain and its wholesale distribution networks.

Continued modernization of hospital pharmacy inventory systems across France, combined with growing supplier investment in regional technical support infrastructure, is supporting steady volume growth through the forecast period. Expanding biologics and specialty drug manufacturing tied to the country’s established pharmaceutical production base is expected to further reinforce this steady contribution through 2035. Continued collaboration between regional drug manufacturers and RFID suppliers on technical specifications is expected to sustain this trajectory through the remainder of the decade across the broader French pharmaceutical market and its distribution infrastructure.

Italy RFID in Pharmaceuticals Market Insights

Italy held a steady revenue share of the Europe RFID in Pharmaceuticals Market in 2025, supported by an established generics manufacturing base and a wholesale distribution network maintaining compliance with Falsified Medicines Directive serialization requirements across the country. Growing investment in item-level verification among regional drug manufacturers continues to support Italy’s consistent contribution to the broader European market. Established logistics infrastructure linking the country’s manufacturing base to national pharmacy networks further supports steady volume growth through the remainder of the forecast period across the broader Italian pharmaceutical supply chain and its distribution network.

Continued modernization of pharmacy inventory systems across Italy, combined with growing supplier investment in regional technical support infrastructure, is supporting steady volume growth through the forecast period. Expanding generics and specialty drug manufacturing tied to the country’s established pharmaceutical production base is expected to further reinforce this steady contribution through 2035. Continued collaboration between regional drug manufacturers and RFID suppliers on technical specifications is expected to sustain this trajectory through the remainder of the decade across the broader Italian pharmaceutical market and its wholesale distribution infrastructure.

Spain RFID in Pharmaceuticals Market Insights

Spain accounted for a steady share of the Europe RFID in Pharmaceuticals Market in 2025, supported by a growing generics and biosimilars manufacturing base and expanding wholesale distribution infrastructure maintaining Falsified Medicines Directive compliance across the country. Growing investment in point-of-manufacture tagging among Spanish drug manufacturers continues to support the country’s consistent contribution to the regional market. Established relationships between domestic suppliers and large pharmaceutical producers further support steady volume growth through the remainder of the forecast period across the broader Spanish pharmaceutical supply chain and its wholesale distribution networks nationwide.

Continued modernization of hospital pharmacy inventory systems across Spain, combined with growing supplier investment in regional technical support infrastructure, is supporting steady volume growth through the forecast period. Expanding biosimilars and specialty drug manufacturing tied to the country’s growing pharmaceutical production base is expected to further reinforce this steady contribution through 2035. Continued collaboration between regional drug manufacturers and RFID suppliers on technical specifications is expected to sustain this trajectory through the remainder of the decade across the broader Spanish pharmaceutical market and its distribution infrastructure.

Market Dynamics

Growth Drivers: Falsified Medicines Directive compliance and expanding biologics manufacturing are increasing demand for item-level and cold-chain RFID tagging.

Continued compliance activity tied to the EU Falsified Medicines Directive is pushing drug manufacturers and wholesale distributors across Europe to maintain and expand item-level RFID verification investment across national healthcare systems. Growing biologics and specialty drug manufacturing is widening demand for sensor-enabled tags capable of continuous cold-chain condition monitoring from production through last-mile pharmacy delivery across the region. Falling tag production costs and expanding chipless product portfolios are further easing adoption among smaller manufacturers and packaging converters previously deterred by cost. Hospital pharmacy automation programs across Germany, France, and the United Kingdom are expected to sustain this trajectory through the remainder of the forecast period.

Restraints: High integration costs and RF performance limitations near metal and liquids continue to complicate deployment decisions.

High integration and validation costs continue to complicate RFID adoption decisions for smaller drug manufacturers and distributors across Europe, particularly where legacy packaging lines require significant retrofitting to accommodate tagging equipment. Reduced RF read performance near metal shelving and liquid-filled containers remains a persistent technical constraint for pharmacy and distribution-center deployments across the region, requiring careful site-specific engineering. Data security and standards fragmentation across different reader and middleware platforms add further complexity to enterprise-wide rollout decisions spanning multiple national healthcare systems. The fact that the Falsified Medicines Directive does not explicitly mandate RFID technology continues to leave some manufacturers evaluating alternative serialization approaches.

Opportunities: Automated bulk verification and sensor-enabled cold-chain monitoring create substantial long-term growth potential.

Expanding demand for automated bulk verification at distribution centers and returns-processing points is opening substantial new RFID deployment opportunities well beyond traditional point-of-manufacture tagging across Europe. Growing adoption of sensor-enabled tags capable of continuous temperature and condition monitoring is creating new product lines tailored to biologics, vaccines, and other temperature-sensitive therapies moving through increasingly complex cross-border distribution networks. Continued supplier investment in sterilization-compatible and chipless formats is also expected to broaden RFID use into vials, syringes, and other historically difficult-to-tag packaging formats, supporting more sustainable long-term category growth across the region through the remainder of the forecast period.

⮞In 2025, Tageos opened a new RFID inlay converting facility in France, a move expected to shorten lead times for European drug manufacturers scaling serialization programs.

Europe RFID in Pharmaceuticals Market key players are:

• Avery Dennison Corporation

• Zebra Technologies Corporation

• Impinj, Inc.

• CCL Industries Inc. (Smartrac)

• Fresenius Kabi AG

• Checkpoint Systems, Inc.

• NXP Semiconductors N.V.

• SATO Holdings Corporation

• Schreiner MediPharm

• Tageos SAS

• GAO RFID Inc.

• Invengo Technology Corp.

• Honeywell International Inc.

• Siemens AG

• Bluesight, Inc.

• Paragon ID Plc

• Turck Vilant Systems

• p-Chip Corporation

• Confidex Ltd.

• Mojix, Inc.

Europe RFID in Pharmaceuticals Market Report Scope: